Skip to main content

Table 2 Association between csDMARDs and BMI with the presence of serum TNFi after 1 year of treatment

From: Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

  OR 95% CI
Age 1.04 0.98–1.11
Male 0.59 0.17–2.14
Disease duration 0.93 0.88–0.99*
TNFi type (ref: infliximab) 0.46 0.15–1.39
csDMARD (ref: use of any csDMARD) 3.82 1.06–13.84*
BMI (ref: normal weight) 18.38 2.24–150.63*
  1. The adjusted multivariable logistic regression analysis included 161 patients. Odds ratio (OR) and 95% confidence interval (CI) were calculated. *p value < 0.05 was considered statistically significant. TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, BMI body mass index